To the best of our knowledge, the outcomes of our mouse study, illustrating the remarkable 90% response rate and the lack of immune-mediated adverse events for the combination of anti-PD-1 and anti-TIGIT antibodies, coupled with the sustained tumour immunity even after 300 days of tumour rechallenge, constitute a promising advancement in the realm of immune checkpoint combinations. The gene discussed is PDCD1; the disease is neoplasm.